National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances

NAC/AEGL-45 March 3-5, 2008

Hilton- Old Town Alexandria 1867 King Street Alexandria, VA

ATTACHMENT 1

AGENDA

Monday, March 3, 2008

| 10:00 a.m. | *Development team meetings: Isocyanates; PBPK issue chemicals (1,1,1-trichloroethane; |
|-------------|---|
| | Ethyl benzene; Tetrachloroethylene); Cyanogen |
| 11:00 | Introductory remarks and approval of NAC/AEGL-44 Highlights (George Rusch, Ernie Falke, and Paul Tobin) |
| 11:15 | Status Update: Ethylphosphonothioic dichloride; methoxymethyl isocyanate (Cheryl Bast) |
| 11:20 | Review of Nitrogen trioxide and Nitrogen tetroxide (George Woodall/Carol Wood) |
| 12:00 p.m. | Lunch |
| 1:00 | Review of Ethyl benzene (John Hinz/Carol Wood/Jim Dennison) |
| 3:00 | Break |
| 3:15 | Progress Report: 1,1,1-Trichloroethane: PBPK Issues (Bob Benson/Sylvia Talmage/Jim |
| | Dennison) |
| 4:15 | Progress Report: Tetrachloroethylene: PBPK Issues (Bob Benson/Claudia Troxel/Jim |
| 4.20 | Dennison) |
| 4:30 | Review of Cyanogen (Glenn Leach /Cheryl Bast) |
| 5:30 | Adjourn for the day |
| Tuesday, Ma | rch 4, 2008 |
| 8:30 a.m. | *Development team meetings: 1,2-Butylene oxide; Ethyl Phosphorodichloridate; |
| | Isocyanates (if needed) |
| 9:30 | Review of Ethyl isocyanate (Susan Ripple/Bob Young) |
| 10:30 | Break |
| 10:45 | Review of Phenyl Isocyanate (Susan Ripple/Bob Young) |
| 12:00 p.m. | Lunch |
| 1:00 | Review of n-Butyl isocyanate; Isobutyl isocyanate; n-Propyl isocyanate; Isopropyl |
| 2.20 | isocyanate; and t-Butyl isocyanate (Susan Ripple/Bob Young) |
| 2:30 | Benchmark Concentration Analysis (Jay Zhao) |
| 3:30 | Break |
| 3:45 | Review of Methyl isothiocyanate (Susan Ripple/ Sylvia Talmage) |
| 5:30 | Adjourn for the day |
| Wednesday, | March 5, 2008 |
| 8:30 a.m. | Review of Ethyl phosphorodichloridate (Gail Chapman/Cheryl Bast) |
| 9:30 | Break |
| 9:45 | Review of 1,2-Butylene oxide (Jim Holler/Sylvia Talmage) |
| 11:45 | Administrative matters |

^{*}See page 2.

12:00 noon

Adjourn meeting

NAC/AEGL Meeting 45: March 3-5, 2008

Chemical: ATTENDANCE 3/3/08 CAS Reg. No.: ATTACHMENT 2 Action: Proposed_____ Interim___ Other____ Chemical Manager: Staff Scientist: NAC Member AEGL1 AEGL 2 AEGL3 NAC Member AEGL1 AEGL2 **AEGL3** LOA LOA John Hinz Henry Anderson Marc Baril Jim Holler Lynn Beasley Glenn Leach Alan Becker Richard Niemeier 1 Robert Benson Susan Ripple Edward Bernas George Rusch, Chair Martha Steele Gail Chapman George Cushmac Daniel Sudakin Ernest Falke Marcel vanRaaij Calvin Willhite David Freshwater Ralph Gingell George Woodall Roberta Grant Alan Woolf Dieter Heinz TALLY PASS/FAIL 4 Hr $PPM, (mg/m^3)$ 10 Min 30 Min 1 Hr 8 Hr AEGL 1)) , (,(,(,(, (**AEGL 2** , () ,() , () , () , (AEGL 3 , (,(, () , (,(LOA * = ≥10% LEL ** = ≥ 50% LEL *** = ≥100% LEL *Safety considerations against the hazard(s) of explosion(s) must be taken into account. ** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account. NR= Not Recommended due to Second by: _____ AEGL 1 Motion by: AEGL 2 Motion by:_____ Second by: Second by: _____ AEGL 3 Motion by: __ Second by: LOA Motion by: Approved by Chair: ______ DFO: ______ Date: _____

1,1,1-Trichloroethane NAC-45, March 3-5, 2008

NRC/NAS Committee on Toxicology, AEGL Subcommittee Comments on 1,1,1-Trichloroethane, July 2000

These comments affect the choice of key studies

AEGL-1 (4-hour exposure to 450 ppm – slight eye irritation [Salvini et al. 1971])

Why choose Salvini et al. (1971) as the key study for AEGL-1?

Give rationale why this is the best human study

Value is inconsistent with several other well-conducted studies

Consider using the 500 ppm for eye irritation in the study of Stewart et al. (1961).

A two-fold intraspecies uncertainty factor is not warranted for slight eye irritation, "a slight, reversible, subjective effect" (i.e., a UF of 1 is sufficient)

Agree with using the same value across time for AEGL-1 But consider raising the 10-minute value

AEGL-2 (3780 ppm for 4 hours - EC₅₀ for ataxia in rats [Mullin and Krivanek 1982])

There are substantial problems with the use of rodent CNS depression

Behavior performance studies are notoriously insensitive and difficult to interpret Rats receive a much higher internal dose of inhaled 1,1,1-trichloroethane than humans

The calculated AEGL-2 values range from 930 ppm to 300 ppm

350 ppm is the TLV

900 ppm was the threshold for lightheadedness in humans (Stewart et al. 1961; 1969; Torkelson et al. 1958)

1900 ppm for 5 minutes – disturbance in equilibrium of human subjects (Torkelson et al. 1958) appears to be a better basis.

Need 10,000-26,000 for light plane anesthesia in humans (Dornette and Jones 1960)

Suggest using 2000 ppm as a reasonable basis for AEGL-2 and using UF of 2.

Make 10-minute value higher

Approaches steady-state in the brain at 30-45 minutes

Use validated PBPK modeling to time-scale

AEGL-3 (6-hour, 7000 ppm estimate of lethality threshold in rats [Bonnet et al. 1980])

Estimated from a graph not much detail... study is in French

The most sensitive subjects inhaling 6000 ppm during surgery did not die

Light plane anesthesia is not lethality

Questioned keeping the values below the threshold for cardiac sensitization because the injected dose of epinephrine in dogs was 10X physiological levels

| | Summary of Interim Values for 1,1,1-Trichloroethane | | | | | | | | | |
|---------------------------------|---|-----------|----------|----------|----------|---|--|--|--|--|
| Classification | 10-Minute | 30-Minute | 1-Hour | 4-Hour | 8-Hour | Endpoint (Reference) | | | | |
| AEGL-1 (Nondisabling) | 230 ppm | 230 ppm | 230 ppm | 230 ppm | 230 ppm | Eye irritation and slight dizziness in humans (Salvini et al., 1971) | | | | |
| AEGL-2 (Disabling) | 930 ppm | 670 ppm | 600 ppm | 380 ppm | 310 ppm | EC ₅₀ for ataxia in rats (Mullin and Krivanek, 1982) | | | | |
| AEGL-3 ^a (Lethal) | 4200 ppm | 4200 ppm | 4200 ppm | 2700 ppm | 2100 ppm | Estimated concentration causing no deaths in rats (Bonnet et al., 1980) | | | | |

^a The 1-hour value was used as the 10-minute and 30-minute values so as not to exceed the threshold for cardiac sensitization of 5000 ppm observed in dogs (Reinhardt et al., 1973).

| | | Effects of Exposure to 1,1,1-Trichloroethane | |
|--|--|--|--|
| Concentration (ppm) | Duration | Effect | Reference |
| Clinical Studies | | | |
| 35-400 | 0.5-6 hours (avg 4 hours) | Effects included no symptoms; no effect on body sway; initial noticeable odor; slight eye irritation; both slower and enhanced neurobehavioral performance (subclinical deficits) | Eight clinical studies |
| 500 (450-561) 500 (498-509) | 6.5-7 hours, 5 days | No consistent symptoms No consistent symptoms | Stewart et al. 1969 Stewart et al. 1975 |
| 500 (6 male subjects) 500 (6 male subjects) 900 (2 male subjects) 910 (2 male subjects) 955 (3 male subjects) 0-2650 (7 subjects) | 1.3 hours 3.1 hours 20 minutes 35 minutes 1.2 hours 15 minutes | Slight eye irritation, 3 of 6 subjects No effects reported Lightheadedness, positive Romberg test in 1 of 2 subjects Lightheadedness, in 1 of 2 subjects, Romberg test difficult Positive Romberg test in 1 of 3 subjects Loss of equilibrium in 2 of 7 subjects at peak of 2650 ppm | Stewart et al. 1961 |
| 546 (450-710) 506 (415-590) 920 (900-1000) 1000 (890-1190) 1900 (1740-2180) | 1.5 hours 7.5 hours 70-75 minutes 30 minutes 5 minutes | NOAEL for subjective symptoms; normal Romberg test Transient odor detection; normal Romberg test Very slight equilibrium disturbance in 3 of 4 subjects, rapid recovery Strong odor; equilibrium not disturbed Noticeable odor; equilibrium disturbance | Torkelson et al. 1958 |
| 10,000-16,000 6000-22,500 (with N ₂ O) Laboratory Animal Stud | 2 minutes No data | Induction of light plane anesthesia Maintenance of light anesthesia during surgical procedures | Dornette and Jones 1960 |
| 1000 (rat) 2000 | 100 minutes 100 minutes | No deficits in neurobehavioral tests Small decrease in response after 1 hour | Warren et al. 1998 |
| 1750 (rat) 3780 | 4 hours 4 hours | No neurobehavioral deficits EC ₅₀ for ataxia | Mullin and Krivanek 1982 |
| 700, 1400 (baboon) 1800, 2100 | 4 hours 4 hours | No change in response in neurobehavioral test No effect on correct responses, decreased responses, 29 and 33% | Geller et al. 1982 |
| 5000 (monkey) 12,500 (rat) | 7 hours 4 hours | Ataxia after 1 hour; trembling of hands after 5 hours Highest non-lethal value (average of 4 studies) | Adams et al. 1950 Hazleton Labs 1989 |
| 15,525 (rat) | 4 hours | Highest non-lethal value | Calhoun et al. 1988 |

Romberg test: standing on one foot with arms extended, both with eyes open and with eyes closed. Equilibrium test: walking heel-to-toe in a straight line for 5 feet.

AEGL-2 Values from the PBPK Modeling (no Uncertainty Factors applied)

| Study | Exposure | CV | 40 | | | | |
|-----------|------------------|-------------|--------|--------|--------|--------|------------|
| Stewart | | CV | 10 min | 30 min | 1 hour | 4 hour | 8 hour |
| | 900 ppm/20 min | 3.91 mg/L | 1440 | 710 | 530 | | |
| Stewart | 910 ppm/35 min | 5.38 mg/L | | | | 390 | 380 |
| | | | 2000 | 980 | 730 | 530 | 520 |
| | 955 ppm/73 min | 7.61 mg/L | 2830 | 1390 | 1020 | 750 | |
| Torkelson | 920 ppm/72.5 min | 7.33 mg/L | 2730 | | | | 740 |
| | 1000 ppm/30 min | | | 1340 | 990 | 730 | 710 |
| | | 5.48 mg/L | 2040 | 1000 | 740 | 540 | 520 |
| Iorkelson | 1900 ppm/5 min | 3.00 mg/L | 1120 | · | | | 530 |
| | | Jo. 30 mg/L | 1120 | 550 | 410 | 300 | 300 |

Note: values based on preliminary revised model and may be different after additional work

| ΔTT | ACHN | 4ENT | 1 |
|-------------|-------------|-------------|---|
| Δ | 41.64 | | 4 |

AEGL for NITROGEN OXIDES

NAC-AEGL #45 [3-5 Mar 08]

Chemical manager Chemical reviewers George Woodall Daniel Sudakin Marc Baril

Principal author

Carol Wood

| ST | Δ | TI | 16 |
|----|---|----|----|

- · Nitrogen dioxide: Interim
- accepted by the NAC
- currently in review by COT
- · Nitrogen tetroxide and Nitrogen trioxide: Draft
 - chemical specific information added to NO₂ document
 - literature search for data

Atmospheric Reactions

 $2NO + O_2 \rightarrow 2NO_2$ (minor at ambient temp) $NO + O_3 \rightarrow NO_2 + O_2$ $NO + HO_2 \bullet \rightarrow NO_2 + HO \bullet$ $NO + RO_2 \bullet \rightarrow NO_2 + RO \bullet$ $NO_2 + HO \bullet \rightarrow HNO_3$ $2NO_2 \rightarrow N_2O_4$

- temperature dependent
- favors NO₂ production

Data Summary for N₂O₄ and N₂O₃ N₂O₄ - Physicochemical properties - Case reports of respiratory complaints after accident - LC₅₀ values for four species; no experimental details - Pulmonary lesions in rats; questionable protocol N₂O₃ - Physicochemical properties - No exposure data Other relevant information No standards or guidelines for N₂O₄ or N₂O₃ Oxides of nitrogen = NO₂ toxicity - NIOSH, EPA, etc. N₂O₄ in rocket emissions but NRC considered NO₂, nitric acid, and HCI **NAC/AEGL Action** Adopt the NO₂ values for these three oxides of nitrogen Include data for N₂O₄ and N₂O₃ in TSD as written

ATTACHMENT 5

AEGL for ETHYLBENZENE

NAC-AEGL #45 [3-5 March 08]

Chemical manager Chemical Reviewers John P. Hinz Jim Holler Iris Camacho

Principal Author

Carol S. Wood

History

- First addressed by the NAC in September, 2006; industry presented unpublished data (Stump 2003)
- Second draft was brought to the NAC in December, 2006; it was decided to look at PBPK modeling for AEGL 2 and 3
 - the NAC discussed and decided upon the key studies and points of departure to use in the model
 - these were communicated to industry and the model was run

AEGL 1: Key Study and POD

- Bardodej and Bardodejova 1961
 - Humans
 - 100 ppm for 8 hours: no complaints or any problems in nine subjects
 - 180 ppm for 8 hours: irritation of respiratory tract and conjunctiva, headaches, sleepiness in eleven subjects

| | • |
|-------------|--|
| | · · · · · · · · · · · · · · · · · · · |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| • | |
| | |
| | |
| | |
| | |
| | |
| • | |
| | |
| | |
| | |
| | |
| | |
| | |
| | ······································ |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

AEGL 2: Key Study and POD

- Cappaert et al. 2002
 - Ototoxicity in female rats
 - 550 ppm, 8 hr/d, 5 days
 - · Pronounced outer hair cell loss
 - Threshold shift measured in mid-frequency hearing range

AEGL 3: Key Study and POD

- Andersson et al. 1981
 - Male rats: highest non-lethal
 - 2000 ppm, 6 hrs: no clinical signs or deaths

PBPK model for Ethylbenzene

- Lisa Sweeney, The Sapphire Group, Inc.
- Supported by ACC EB Panel
- · Peer review by Jim Dennison
- AEGL 2 and 3 run based on POD chosen by NAC

| | | 15, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10 | |
|---|---------------------------------------|--|---------------------------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| • | · · · · · · · · · · · · · · · · · · · | | ··· |
| | | | |
| | - | | |
| | | | |
| | | | |
| | | | |
| | · · · · · · · · · · · · · · · · · · · | | |
| | | | |
| | · | | |
| | · · · · · · · · · · · · · · · · · · · | | · · · · · · · · · · · · · · · · · · · |
| | | | |

| | ummary of Pr (PBPK model | • | | - | |
|--------|-----------------------------|----------|---------|---------|---------|
| | 10-min | 30-min | 1-hr | 4-hr | 8-hr |
| AEGL 1 | 10 ppm | 10 ppm | 10 ppm | 10 ppm | 10 ppm |
| AEGL 2 | 4000 ppm | 1400 ppm | 710 ppm | 200 ppm | 120 ppm |
| AEGL 3 | 1400 ppm | 810 ppm | 580 ppm | 360 ppm | 320 ppm |

UF = 10 for all

Why is AEGL 2 > AEGL 3?

- AEGL 3 (POD = 2000 ppm for 6 hr, highest nonlethal)
 - Based on peak blood concentrations (peak CR)
 - Endpoint (death) measured after single exposure
- AEGL 2 (POD = 550 ppm, 8 hr, 5 days, ototoxicity)
 - Based on cumulative exposure (AUC)
 - Endpoint (ototoxicity) measured after 5 exposures

Options

- 1. Use AEGL 2 values from model, but not AEGL 3 values (but data are available)
- 2. Use AEGL 3 values from model, but not AEGL 2 values (but data are available)
- 3. Use model with different UFs (see upcoming slide)
- 4. Use POD and calculate the old fashioned way (as presented in TSD; may need different UFs)

| | • | | | | | | | |
|---|------|-------------|---|---|-------------|-------------|-------|---|
| | | | | | | | | |
| _ | | | | | | | | |
| | | | | | | | | |
| _ | | | - | | | | | |
| _ | | | | | | | | |
| | | | • | | | | | - |
| | | | | - | | | | |
| | , | | | | | | | |
| | | | | | • | | | |
| _ | | | | | | | | - |
| _ | | | | | | | | |
| _ | | | | | | | | • |
| _ | | <u>-</u> | | | | | , | |
| _ | | 4 | | | | | | |
| _ | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| Summary of Proposed AEGL values for Ethylbenzene (calculated from data) | | | | | | | |
|---|---------|---------|---------|--------|--------|--|--|
| | 10-min | 30-min | 1-hr | 4-hr | 8-hr | | |
| AEGL 1 (UF = 10) | 10 ppm | 10 ppm | 10 ppm | 10 ppm | 10 ppm | | |
| AEGL 2 (UF = 30) | 46 ppm | 46 ppm | 37 ppm | 23 ppm | 18 ppm | | |
| AEGL 3 (UF = 30) | 150 ppm | 150 ppm | 120 ppm | 76 ppm | 50 ppm | | |

UF: 10 for intra- for systemic toxicity

3 for inter- because effects consistent between species

Application of UFs

- UF_H = 10 because the mechanism of systemic toxicity is unknown
 - *Reduce to 3 for AEGL 3 and AEGL 1
 - Mechanism for lethality is probably CNS depression
 - Mechanism for ototoxicity is unknown so leave as 10 for AEGL 2
 - Irritation threshold is basis for AEGL 1
 - Reduce to 3 for all AEGL levels:
 - mechanism is probably CNS depression or contact irritation
 - limited data suggest steady-state reached quickly in both rat and human
 - rapid metabolism with little tissue retention
 - toluene, xylenes, 1,2-dichloroethene use 3 [Among humans the minimum alveolar concentration (MAC) for volatile anesthetics (CNS) hypically varies by about 2-3 fold.]

Application of UFs

- UF_A = 3 because clinical signs and systemic effects were consistent between experimental animal systems
 - *Reduce to 1 for AEGL 3:
 - · CNS effects do not differ
 - May not be same endpoint for AEGL 2
 - Reduce to 1 for AEGL-2 and -3:
 - toluene and xylenes use 1

| | | | 4 |
|-----|------|--|------|
| | | | |
| | - | | |
| | ٠ | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| . * | | | |

ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs)

CYANOGEN

NAC/AEGL-45 March 3-5, 2008 Alexandria, VA

ORNL Staff Scientist: Cheryl Bast

Chemical Manager: Glenn Leach

Chemical Reviewers: Henry Anderson and Gail Chapman

Reported that rat data suggest that cyanogen is less acutely toxic than cyanide by a factor of 10

HOWEVER:

Analysis of available rat data suggests that this assumption may be true for very short exposure durations (up to approx 15 minutes), but not for longer durations (30 minutes to 1 hour).

| TABLE 1. Comparative rat toxicity of HCN and cyanogen | | | | | | | |
|---|-------------------------------|------------------|-------------------|--|--|--|--|
| Concentration (ppm) | Exposure duration (min) | HCN Endpoint | Cyanogen Endpoint | | | | |
| 400-500 | 5 | LC ₅₀ | - | | | | |
| 4000 | 7.5 | - | Mortality: 3/6 | | | | |
| 196 | 15 | LC ₅₀ | - | | | | |
| 1000 | 15 | - | Mortality: 0/6 | | | | |
| 2000 | 15 | · <u>-</u> | Mortality: 6/6 | | | | |
| 150-200 | 30 | LC ₅₀ | - | | | | |
| 500 | 30 | - | Mortality: 0/6 | | | | |
| 1000 | 30 | - | Mortality: 6/6 | | | | |
| 120-140 | 60 | LC ₅₀ | • | | | | |
| 250 | 60 | - | Mortality: 0/6 | | | | |
| 400 | 60 | - | Mortality: 6/6 | | | | |

Cyanogen is structurally similar to cyanide and other nitriles.

$N \equiv C - C \equiv N$

Reportedly converted in the body partly to hydrogen cyanide and partly to cyanic acid (HOCN)

Reportedly hydrolyzes to yield one mole of hydrogen cyanide and one mole of cyanate

The mechanism of toxicity of cyanogen is reportedly similar to that of hydrogen cyanide (HCN)

Qualitatively, many clinical signs noted in cyanogen-exposed animals are similar to those noted in cyanide-exposed animals.

However, at relatively low concentrations, cyanogen appears to be much more irritating than hydrogen cyanide.

STEEP CONCENTRATION-RESPONSE CURVE

McNerney and Schrenk (1960): Rats

0% mortality: 100% mortality:

1000 ppm for 15-min 1000 ppm for 30-min

0% mortality: 100% mortality:

500 ppm for 30-min 1000 ppm for 30-min

0% mortality: 100% mortality:

400 ppm for 45-min 500 ppm for 45-min

0% mortality: 100% mortality: 250 ppm for 60-min

400 ppm for 60-min

| | AEGL- | 1 Values for C | yanogen | | | |
|---------------------------|---------|----------------|----------|----------|--|--|
| 10-min 30-min 1-h 4-h 8-h | | | | | | |
| 2.7 ppm | 2.7 ppm | 0.90 ppm | 0.90 ppm | 0.90 ppm | | |

Species:

Human

Concentration: Time: 8 ppm

Endpoint:

6 minutes NOEL for ocular and nasal irritation (irritation

was noted at next highest concentration of 16 ppm

for 6 or 8 minutes)

Reference:

McNerney and Schrenk, 1960

Time Scaling:

None Applied. Minor contact irritation.

Uncertainty Factors:

Intraspecies: 3

Contact irritation is a portal-of-entry effect and is

not expected to vary widely between individuals.

Interspecies: 1

Human data

Modifying Factor:3

Applied to the 1-, 4-, and 8-hour time points because of the lack of human data beyond 8-minutes and because of the potential for a systemic effect from the cyanide metabolite. (Similar to Methacrylonitrile)

| AEGL-3 Values for Cyanogen | | | | | | |
|----------------------------|--------|--------|--------|--------|--|--|
| 10-min | 30-min | 1-h | 4-h | 8-h | | |
| 150 ppm | 45 ppm | 21 ppm | 11 ppm | 11 ppm | | |

Species:

Rat

Concentration:

Range of 250 to 400 ppm

Time:

Range of 7.5 to 120 minutes

Endpoint:

Lethality threshold (LC01) calculated using probit-

analysis dose-response ten Berge program

Reference:

McNerney and Schrenk, 1960

Time Scaling:

10-min, 30-min, and 1-hr values:

c" x t = k, where the exponent, n, is 0.90, as determined by analysis of rat lethality data using ten Berge (2006) software.

4- and 8-hour values:

Modifying factor of 2 applied to the 1-hour AEGL-3 value to derive the 4- and 8-hour AEGL-3 values. (Similar to HCl and HF)

Using the calculated probit values (and UFs described below), yields 4-and 8-hour AEGL-3 values of 4.5 and 2.1 ppm, respectively.

These values are inconsistent with the repeated-exposure data in both monkeys and rats (Lewis et al., 1984).

Rats repeatedly exposed to 25 ppm cyanogen 6 hours/day, 5 days/week for up to 6 months, experienced only decreased body weight

Monkeys similarly exposed showed only marginal behavioral effects

No effects were noted in either species similarly exposed at 11 ppm.

| | AEGL-2 Values for Cyanogen | | | | | | |
|--------|----------------------------|---------|---------|---------|--|--|--|
| 10-min | 30-min | 1-h | 4-h | 8-h | | | |
| 50 ppm | 15 ppm | 7.0 ppm | 3.7 ppm | 3.7 ppm | | | |

Endpoint:

Three-fold reduction of AEGL-3 values

Approach justified by steep concentration-response relationship

McNerney and Schrenk (1960): Rats

0% mortality:

1000 ppm for 15-min

100% mortality:

1000 ppm for 30-min

0% mortality:

••

100% mortality:

500 ppm for 30-min 1000 ppm for 30-min

0% mortality:

400 ppm for 45-min

100% mortality:

500 ppm for 45-min

0% mortality: 100% mortality: 250 ppm for 60-min 400 ppm for 60-min

Uncertainty Factors:

<u>Intraspecies: 3:</u> Considered sufficient due to the steep concentration-response curve

Interspecies: 3

Use of the full default interspecies UF of 10 would yield AEGL-3 values that are less consistent with the overall database.

AEGL-3 values derived with a total UF of 30:

| 10-min | 30-min | 1-hr | 4-hr | 8-hr |
|--------|--------|---------|---------|---------|
| 51 ppm | 15 ppm | 7.0 ppm | 3.7 ppm | 3.7 ppm |

Humans exposed to 8 ppm cyanogen for 6 min experienced no irritation; Humans exposed to 16 ppm for 6 min experienced transient ocular and nasal irritation (McNerney and Schrenk, 1960).

Rats and monkeys repeatedly exposed to 11 ppm cyanogen 6 hours/day, 5 days/week for up to 6 months experienced no treatment-related adverse effects.

Rats repeatedly exposed to 25 ppm cyanogen 6 hours/day, 5 days/week for up to 6 months experienced only decreased body weight, and monkeys similarly exposed showed only marginal behavioral effects (Lewis et al., 1984).

SUPPORT FOR AEGL-3 VALUES:

If the actual experimental concentrations causing no death in rats (McNerney and Schrenk, 1960) are divided by a total UF of 10, the resulting values support the proposed AEGL-3 values.

No death was noted in rats exposed to 2000 ppm for 7.5 minutes or 1000 ppm for 15 minutes.

Applying the UF of 10, would yield a 7.5 minute value of 200 ppm and a 15 minute value of 100 ppm, values which encompass the derived 10-minute AEGL-3 value of 150 ppm.

No deaths were noted in rats exposed to 500 ppm for 30 minutes; applying the UF of 10, yields a value of 50 ppm, which is in agreement with the derived 30-minute AEGL-3 value of 45 ppm.

No deaths were noted in rats exposed to 250 ppm for 60 minutes; applying the UF of 10 yields a value of 25 ppm, which is in agreement with the derived 60-minute AEGL-3 value of 21 ppm.

| | Tener - In Photo | • [(| 0 0 | | - | • ‡ † | 4 |
|--|------------------|---------------------|-----|-------------|----------|--------|----------------|
| | | | | | П | | 1 8 |
| | | | | | H | | 8 |
| Data | | | | | | | § |
| Chemical Toxicity - TSD All Data Cyanogen | | | | | APRIL.3 | | 96 |
| oxicfty - TE Cyanogen | | | (|) . | 2 | | 240 Minutes |
| nical To | | | • | | | i-Tear | 180 Mir |
| Che | | | | | П | | = |
| | • | | | | 1 | | ž |
| | | | | | ğ | | 8 |
| | | • • | 8. | | 1 | | |
| 000001 | 8 | 3 • 5 | 3 5 | | <u> </u> | - | + 0 |

| Extant Standards and Guidelines for Cyanogen | | | | | | | |
|--|-------------------|---------|----------|----------|----------|--|--|
| | Exposure Duration | | | | | | |
| Guideline | 10 min | 30 min | 1 h | 4 h | 8 h | | |
| AEGL-1 | 2.7 ppm | 2.7 ppm | 0.90 ppm | 0.90 ppm | 0.90 ppm | | |
| AEGL-2 | 50 ppm | 15 ppm | 7.0 ppm | 3.7 ppm | 3.7 ppm | | |
| AEGL-3 | 150 ppm | 45 ppm | 21 ppm | 11 ppm | 11 ppm | | |
| TLV-TWA (ACGIH) | | | | | 10 ppm | | |
| MAC (The Netherlands) | | | | | 10 ppm | | |
| MAK (Germany) | | | | | 5 ppm | | |
| NIOSH REL | | | | | 10 ppm | | |

| Exposure Concentration | Exposure Duration | Incide | Incidence of subjects experiencing effects | riencing effects |
|----------------------------|----------------------|-------------|--|------------------|
| | | Odor | Ocular Irritation | Nasal Irritation |
| 8 ppm | 6 min. | <i>L</i> /0 | 1/0 | 2/0 |
| 16 ppm | 6 min. | 5/0 | 5/5 | 4/2** |
| 16 ppm | 8 min. | <i>L</i> /0 | LIL | LIL |
| *McNerney and Schrank 1060 | Schrent 1960 | | | |

"McNerney and Schrenk, 1960. **The subject without irritation had mild cold symptoms.

| TABLE 3 | 3. Acute inhalation of cyanogen | in male albino rats* |
|---------------------|---------------------------------|----------------------|
| Concentration (ppm) | Exposure duration (min) | Mortality incidence |
| 4000 | 7.5 | 3/6 |
| 4000 | 15 | 6/6 |
| 2000 | 7.5 | 0/6 |
| 2000 | 15 | 6/6 |
| 1000 | 15 | 0/6 |
| 1000 | 30 | 6/6 |
| 500 | 30 | 0/6 |
| 500 | 45 | 6/6 |
| 400 | 45 | 0/6 |
| 400 | 60 | 6/6 |
| 250 | 60 | 0/6 |
| 250 | 120 | 4/6 |

n-BUTYL ISOCYANATE (CAS Reg. No. 111-36-4)

CH₃-CH₂-CH₂-CH₂-N=C=O

ATTACHMENT 7

n-BUTYL ISOCYANATE Human Data

- o Du Pont, 1986: industrial hygiene survey
 - o 5 to 10 ppb (0.005 to 0.01 ppm) resulted in ocular irritation
 - o 50 ppb (0.05 ppm) normal work operations were not possible but not expected to impair escape

n-BUTYL ISOCYANATE **Animal Lethality Data**

- o IRDC (1965): acute inhalation toxicity
 - o 6 & Sprague-Dawley rats/group) exposed to 5.5, 7.9, 10.9., 12.0, 18.9, 21.7, 27.9, 28.2, or 34.6 mg/m³ (1.4, 1.9, 2.7, 3.0, 4.7, 5.4, 7.0, 7.1, 8.7 ppm) for 1 hr
 - o 14-day observation
 - o 1-hr LC₅₀ of 15.2 mg/m³ (12.1-19.0 95% c.i.)

n-BUTYL ISOCYANATE

- o Pungent smelling liquid with a high vapor pressure
- o Intermediate in the manufacture of chemicals, dyes, and pesticides
- o Respiratory tract and ocular irritation

n-BUTYL ISOCYANATE Animal Lethality Data

| Lethality in rats exposed to n-butyl isocyanate for 4 hours. | | | | | | |
|--|--------------------------|---------------------------------|---------------------------------|--|--|--|
| Exposure | Mortality | | | | | |
| Concentration (ppm) | During exposure | 14 days post exp. | 30 days post exp. | | | |
| 12.5 17.5 22 31.5 53.5 | 0/6 0/6 0/6 2/6 | 0/6 2/6 2/6 2/6 6/6 | 2/6 3/6 5/6 6/6 6/6 | | | |

Du Pont, 1968.

n-BUTYL ISOCYANATE Animal Lethality Data

- o Pauluhu and Eben (1991): repeat-exposure lung function study
 - 20 d'Wistar rats exposed (head-nose only) to 0, 1.09, 6.22, 14.67, and 25.97 mg/m³ (analytical; equivalent to 0, 0.27, 1.55, 3.67, and 6.49 ppm) for 5 hrs/day for 5 days
 - o 5-wk observation
 - o no clinical signs in rats of the 1 or 6 mg/m3 (0.25 or 1.5 ppm) groups
 - o 12 of 20 rats of the highest exposure group died during post exposure week 2
 - o delayed lethality was the result of obstructive and progressive lung damage with associated severe disturbance of ventilatory perfusion

| | Lethality o | of rats exposed to n-butyl isocyanate vapor for one hour(IRDC, 1965) |
|-----------------------------------|-------------------------|---|
| Concentration (mg/m³) [ppm] | Lethality at 14 days | Comments |
| 5.5 [1.4] | 0/6 | No deaths; 4/6 no gross lesions; 2/6 had 8 mm area of congestion in lungs |
| 7.9 [1.9] | 1/6 | Death at 1 day post exposure; in the 5 survivors, lungs remained inflated after sacrifice; 4/5 exhibited mucus in traches and bronchi; 2/5 had lungs with dark areas or areas of consolidation; 1/5 with gastric edema and hemorrhage in 4 survivors, lungs remained inflated after sacrifice; ½ survivors exhibited fluid in small intestine |
| 10.9 [2.7] | 2/6 | Deaths at post exposure day 9, and day 13 post exposure (hungs inflated after sacrifice); consolidation/congestion and dark areas in lungs |
| 12.[3.0] | 0/6 | No deaths; no details regarding nonlethal effects |
| 18.9 [4.7] | 6/6 | 5 Deaths at day 2, 1 at day 13 post exposure; lungs with dark foci/consolidation, ffuid in g.i. tract |
| 21.7 [5.4] | 4/6 | 2 Deaths at day 2, 1 each at days 9, and 11 post exp. |
| 27.9 [7.0] | 6/6 | 2 Deaths on 1st day, 4 deaths at day 1 post exp. |
| 28.2 [7.1] | 6/6 | 1 Death on day of exposure, 5 at day 1 post exp. |
| 34.6 [8.7] | 6/6 | 6 Deaths on day of exposure |

n-BUTYL ISOCYANATE Animal Lethality Data

o Bayer AG (1978)

- o da 9 Wister rats: no experimental details
- o 1-hr LC₉: 425 mg/m³ (280-646 mg/m³ 95% c.i.; equivalent to 106 ppm, 70-162 ppm, 95% c.i.)
- o 4-hr LC_m: <90 mg/m³ (<22.5 ppm) males
- o 4-hr LC_{se}: ~ 80 mg/m³ (20 ppm) females
- o Du Pont & Co. (1968): lethality assay
 - o 6 d ChR-CD rats exposed to 12.5, 17.5, 22, 31.5, 33.5 ppm (analytical; purity not specified) for 4 hours
 - o irregular breathing, hyperemia, gasping, pale ears and lacrimation during exposure
 - o 4-hr LC₉₀: 15.6 ppm (13.3-18.2 ppm, 95% c.i.)
 - o post-exposure observations:
 - 10-20% loss of body weight during the first day, respiratory distress characterized by gasping, labored breathing, congestion and rales, red discharge from the eyes
 - all exposures resulted in some deaths during the 30-day observation period
 - pathology findings: dark red-colored, edematous lungs, necrosis and desquamation of respiratory epithelium, and signs of increased capillary permeability
 - surviving rats exhibited signs of regeneration of bronchial epithelium and proliferation of connective tissue resulting in fibrotic changes and atelectasis
 - bronchopneumonia was evident in many rats by 14 days post exposure

n-BUTYL ISOCYANATE Animal Nonlethal

- Pauluhn et al. (1990): pulmonary function, arterial blood gases, acid-base status, and bronchioalveolar lavage fluid (BALF) composition
 - o groups of 20 & Wistar rats exposed (head-only) for 4 hours to n-butyl isocyanate (technical grade; 99.5%) at concentrations of 7.6, 23.5, and 55.2 mg/m³ (analytical; equivalent to 1.9, 5.9, and 14 ppm)
 - 1.9 ppm: transient clinical signs (hypothermia, bradypnea, and irritation of mucous membranes) during the first day
 - o 5.9 and 14 ppm: signs of severe respiratory distress were observed
 - 5.9 ppm group: resolved within one week
 - 14 ppm group: persisted through the 4-week observation period
 - o high-dose rats
 - gross findings of consolidation, distention, hemorrhagic areas, edema, and pleural effusions
 - microscopic changes included increased numbers of alveolar macrophages, perivascular round-cell infiltration, focal fibroproliferative reactions, emphysema, thickening of the septa, and pneumonia.
 - o Summary
 - 4-hour exposure to 1.9 ppm: minor transient clinical effects that fully resolved with 24
 hours
 - 4-hr exposure to 5.9 ppm: notable effects which resolved within one week
 - 4-hr exposure to 14 ppm: persistent clinical effects and notable histopathological findings consistent with significant pulmonary injury.

n-BUTYL ISOCYANATE AEGL-1

| | AEG | L-I values for n-b | utyl isocyanate (pr |)m) | |
|----------------|--------|--------------------|---------------------|--------|--------|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h |
| AEGL-1 | 0.0017 | 0.0017 | 0.0017 | 0.0017 | 0.0017 |

- Key study: Du Pont (Du Pont de Nemours & Co.) 1986. n-Butyl isocyanate industrial hygiene survey.

 Personal Communication, Central Research and Development Department, Haskell Laboratory for Toxicology and Industrial Medicine.
- Critical effect/POD: occupational exposure; noticeable eye irritation at exposures of 0.005 to 0.01 ppm; the lower range of 0.005 ppm was selected as the point-of-departure for AEGL-1 development.

Uncertainty factors: Total uncertainty factor adjustment is 3

<u>Interspecies</u>: 1; occupational exposure data; the critical effect and point-or-departure (POD) pertain to humans, no interspecies uncertainty factor is necessary.

<u>Intraspecies</u>: 3; because the critical effect was "noticeable" irritation and involved workers who were likely familiar with the effects of u-butyl isocyanate, a 3-fold uncertainty adjustment was applied in the development of the AEGL-1 values.

Modifying Factor: none

Time scaling: not applicable; direct-contact irritant (NRC, 2001)


n-BUTYL ISOCYANATE Animal Lethality Data

| Leti | ality in rats following single | acute exposure to n-butyl isocynnate | | | |
|---|---|--|--|--|--|
| Study | Lethality benchmark | Comments | | | |
| IRDC, 1965 | 1-hr LC ₂₀ : 3.8 ppm | Deaths delayed 1 to 13 days | | | |
| Du Pont & Co., 1968 4-hr LC _m : 15.6 ppm Post exposure deaths; time to death was to exposure concentration | | | | | |
| Bayer AG, 1978 | 1-hr LC ₂₀ : 106 ppm 4-hr LC ₂₀ : <22.5 ppm (♂) 4-hr LC ₂₀ : ≈18 ppm (♀) | to the second se | | | |

n-BUTYL ISOCYANATE Animal Nonlethal

- o IRDC (1965): 1-hour exposure of rats
 - no deaths occurred in a groups of 6 rats exposed to n-butyl isocyanate 5.5 mg/m³ for 1 hour
 - o no deaths among 6 rats exposed to 12.0 mg/m3 for 1 hour
 - lethality occurred at 7.9 and 10.9 mg/m³ (absence of lethality at 12.0 mg/m³ is likely a function of small group size)
 - clinical signs: hypoactivity, increased grooming, and escape behavior during exposure only, salivation, lacrimation, and dyspnea.

| AEGL values for n-butyl isocyanate (ppm) | | | | | | | |
|--|--------|----------|--------|--------|--------|--|--|
| Classification | | 30-min . | I-h | 4-h | 8-h | | |
| AEGL-1 (Nondisabling) | 0.0017 | 0.0017 | 0.0017 | 0.0017 | 0.0017 | | |
| AEGL-2 (Disabling) | 0.017 | 0.017 | 0.017 | 0.017 | 0.017 | | |
| AEGL-3 (Lethality) | 0.22 | 0.22 | 0.18 | 0.11 | 0.057 | | |



n-BUTYL ISOCYANATE AEGL-2

| | · · · · · · · · · · · · · · · · · · · | | | | |
|----------------|---------------------------------------|--------------------|--------------------|-------|-------|
| | AEG | L-2 values for n-t | utyl isocyanate (p | pm) | |
| Classification | 10-min | 30-min | 1-h: | 4-h | 8-h |
| AEGL-2 | 0.017 | 0.017 | 0.017 | 0.017 | 0.017 |

Key study: Du Pout (Du Pout de Nemours & Co.) 1986. n-Butyl isocyanate industrial hygiene survey.

Personal Communication, Central Research and Development Department, Haskell Laboratory for Toxicology and Industrial Medicine.

Critical effect/POD: the occupational exposure analysis stated that exposure to 50 ppb (0.05 ppm) for a nonspecified duration was considered incompatible with normal work operations but not considered escape impairing

Uncertainty factors: Total nucertainty factor adjustment is 3

<u>Interspecies:</u> 1; occupational exposure data; the critical effect and point-or-departure (POD) pertain to humans, no interspecies uncertainty factor is necessary.

Intraspecies: 3; the 50 ppb (0.05 ppm) exposure from the Du Pont (1986) report is considered a protective POD for AEGL-2 derivation because the ocular irritation was neither escape impairing nor irreversible in humans. Although the 0.05 ppm exposure concentration is a protective POD for AEGL-2 derivation, it is assumed that the worker population upon which this is based was accustomed to the irritant effects of n-butyl isocyanate and that sensitive responders may experience similar effects at lower exposures. Therefore, an intraspecies uncertainty factor of 3 was applied for deriving the AEGL-2 values.

Modifying Factor: none

Time scaling: not applicable; direct-contact irritant (NRC, 2001)

n-BUTYL ISOCYANATE AEGL-3

| | AEG | L-3 values for n-b | outyl isocyanate (p) | | |
|----------------|--------|--------------------|----------------------|------|-------|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h |
| AEGL-3 | 0.22 | 0.22 | .: 0.18 | 0.11 | 0.057 |

Key study: Du Pont (Du Pont de Nemours & Co.) 1968. Acute inhalation toxicity; isocyanic acid n-butyl ester. Haskell Laboratory for Toxicology and Industrial Medicine. Report No. 289-68, MR No. 581-243.

Critical effect/POD: 4-hr BMCL₀₅ of 3.35 ppm as estimated of lethality threshold

Uncertainty factors: Total uncertainty factor adjustment is 30

<u>Interspecies</u>: 10; lethality data for n-butyl isocyanate are available for only one species and there is no information regarding lethality in humans.

<u>Intraspecies</u>: 3; although the lethal response in rats exposed to n-butyl isocyanate exhibits latency, the initial insult appears to be the result of pulmonary damage. This mode of action is not likely to vary considerably across individuals although dosimetric factors may be instrumental. To account for possible dosimetric variability, the intraspecies uncertainty factor is 3.

Modifying Factor: none

Time scaling: $C'' \times t = k$, where n = 1 or 3

| ETHYL IS | OC | YANATE |
|-----------|-----|-----------|
| (CAS Reg. | No. | 109-90-0) |

o Pungent smelling liquid with a high vapor pressure

CH₃-CH₂-N=C=O

- o Intermediate in the manufacture of pharmaceuticals and pesticides
- o Respiratory tract and ocular irritation
- o Very limited data

NAC/AEGL-45 Alexandria, VA March 3-5, 2008

ORNL Staff Scientist: Chemical Manager: Chemical Reviewer: Chemical Reviewer: Robert A. Young Susan Ripple David Freshwater Ralph Gingell

ETHYL ISOCYANATE

- o Human data none
- o Animal data
 - o rats only (Eastman Kodak, 1964)
 - 3 rats/group
 - exposure concentration by wt./volume

| r | | THE PARTY OF | TO OF THE 10 CITYL MOCY | Explorance of the to comit specifications (Cartesian Explorated 1700) |
|-------|--------------------|--------------|-------------------------|---|
| Cone. | Duration Mortality | Mortality | Time of death | Clinical signs: time noted |
| | 6-hr | 6/3 | | Blepkarism: 1-min |
| | | | | Pilo-erection: 1-min |
| | | | | Lacrimation: 15-min |
| | | | | Eyes are dark: 1-hr |
| | | • | | Nasal discharge: 1-hr, 20-min |
| | 6-br | 3/3 | 0/3 dead during | Blepharism: 1-mis |
| : 1 | | | exposure | Pilo-erection: 1-min |
| | | | 3/3 dead in 24-hrs. | Lacrimation: 1-min |
| | | | | Eves are dark: 20-min |
| | | | | Gasping and dyspues: 20-min |
| | | | | Ptyalism: 55-min |
| 206 | 2.8 km | 3/3 | 1 dead in 2.25 hrs | Blepharism: immediately apon exposure |
| | | | 1 dead in 2.3-hrs | Pilo-erection: immediately upon exposure |
| | | | 1 dend in 2.8 hrs | Lacrimation: immediately upon exposure |
| | | | | Ptyalism: 1-min |
| | | | | Eyes are dark: 5-min |
| | 1.0 | | | Gasping and dyspnes: 5-min |
| 1 | | | | Nasal discharge: 15-min |
| | | | | Prostration: 1-hr, 35-min |
| | | | 3 | Conventainner 2-hr. 14-min |

ETHYL ISOCYANATE AEGL-3

| | | GL-3 values for eti | hyl isöcyanate (pp | mm) | |
|----------------|--------|---------------------|--------------------|------|------|
| Classification | 10-min | 30-min | 1-b | 4-h | 8-h |
| AEGL-3 | 0.69 | 0.69 | 0.54 | 0.34 | 0.23 |

Key study: Eastman Kodak. 1964. Toxicity and Health Hazard Summary. Ethyl Isocyanate. Laboratory of Industrial Medicine, Eastman Kodak, Co., Rochester, NY. OTS0528345.

Critical effect/POD: NOAEL for lethality -27 ppm for 6-hr; lethality occurred at next highest concentration (82 ppm for 6-hr).

Uncertainty factors: Total uncertainty factor adjustment is 30

Interspecies: 10; lethality data for ethyl isocyanate are available for only one species; no human data.

Intraspecies: 3; clinical signs consistent with contact irritation which is not likely to vary considerably across individuals, although dosimetric factors may be instrumental. To account for possible dosimetric variability, the intraspecies uncertainty factor is 3 is considered sufficient. The intraspecies uncertainty factor of 3 is also supported by the steep concentration-response with regard to lethality (0% mortality in rats exposed to 27 ppm and 100% mortality at 82 ppm for 6-hr; Eastman Kodak, 1964).

Modifying Factor: 3: sparse data base

Time scaling: $C'' \times t = k$, where n = 1 or 3

| AEGL values for ethyl isocyanate (ppm) | | | | | | | | |
|--|--------|--------|------|------|-------|--|--|--|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h | | | |
| AEGL-1 (Nondisabling) | NR | NR · | NR | NR . | NR | | | |
| AEGL-2 (Disabling) | 0.23 | .0.23 | 0.18 | 0.11 | 0.077 | | | |
| AEGL-3 (Lethality) | 0.69 | 0.69 | 0.54 | 0.34 | 0.23 | | | |

NR: Not Recommended. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 are without effect.

ETHYL ISOCYANATE AEGL-1

| | AE(| IL-1 values fo | r ethyl isocyan | ate | |
|----------------|--------|----------------|-----------------|-----|-----|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h |
| AEGL-1 | NR | NR | NR | NR | NR. |


NR: Not Recommended. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 are without effect.

o Not recommended - insufficient data

ETHYL ISOCYANATE AEGL-2

| 9 1 7 10 7 | AEGL- | 2 values for et | hyl isocyanate | (ppm) | |
|----------------|--------|-----------------|----------------|-------|-------|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h |
| AEGL-2 | 0.23 | 0.23 | 0.18 | 0.11 | 0.077 |

- o Insufficient data
- AEGL-2 values estimated as three-fold reduction of AEGL-3 values (NRC, 2001)



PHENYL ISOCYANATE Animal Lethality Data

| | | Summary o | f America (g.) | Hality Ber | elmerks. | 1111 | | |
|-----------------|-------------|---------------------|----------------|---|---------------------------------------|---------------|-----------|--------|
| THE IStudy | Lethality b | 機構を担める | | 在 1000 000 000 000 000 000 000 000 000 0 | O O O O O O O O O O O O O O O O O O O | | 建设 | an I |
| Monsanto, 1954 | -67 ppm: 12 | 2.5.hrs | Rate 100 | Welliality | , no rate die | | etor 4 hr | |
| Mobay, 19782 | 4-brit Cari | 2-6 ppm | Balls area | sat 8-12 | days post ei | District Land | * | 學科學 |
| Tinp Chem. Ind. | H-tir LCa: | | Section 1 | iyed lethali | y Mark | in Jacobs | 1 | 100 |
| Lta: 1980a | | | | 1 | | | | 4 |
| BayeraG 1981a | ~1690 ppm | 3 in and electric | 100 | Alethality | | | #### ## | weter. |
| | | | | e jenisty | 30 150 Lan | | | - 1 |
| | 1600 ppm | 30 Maria 162 | | lethelity | at 32-59 | | 7 | |
| Baver AG. 1991a | | diron 2 | Tiers imo | r deaths at | 200 | Semposure : | | |

o Monsanto (1954)

o rats exposed to 0.33 mg/L (~67 ppm) died at 1 hour, 2 hours and 2.5 hours of exposure

o second experiment rats were exposed for 4 hours to 0.14 mg/L (~29 ppm): all rats survived.

o Mobay (1978)

o 1-hr LC₅₆ of 12.6 ppm (8.4-19.0; 95% c.i.)

o 4 & 4 \(\frac{1}{2} \) /group (up to 80 ppm)

o 8-12 days latency

ORNL Staff Scientist: R
Chemical Manager: Si
Chemical Reviewer: D
Chemical Reviewer: R

Robert A. Young Susan Ripple David Freshwater Ralph Gingell PHENYL ISOCYANATE (CAS Reg. No. 103-71-9)

PHENYL ISOCYANATE

o Pungent smelling liquid with a high vapor pressure

NAC/AEGL-45 Alexandria, VA March 3-5, 2008

- o Intermediate in the manufacture of pharmaceuticals and pesticides
- o Respiratory tract and ocular irritation

PHENYL ISOCYANATE Animal Nonlethal

o Pauluhn et al. (1995) (pilot study for 2-week study)

o & Wistar rats (4/group) exposed (nose-only) to 0, 1.9, 5.14, or 12.92 mg/m³ (equivalent to 0, 0.4, 1.1, and 2.7 ppm; analytically determined)) for 45 minutes

o 1.1 mg/m³ (0.2 ppm) estimated threshold exposure for upper respiratory tract sensory irritation.

o Pauluhn et al., (1995)

20 & Wistar rats exposed (nose-only) for 6 hrs/day, 5 days/wk to 0, 1.04, 4.1, 7.18, or 10.39 mg/m³ (0, 0.2, 0.8, 1.5, or 2.1 pom)

o no clinical signs in 0.2 or 0.8 ppm groups

o incidences of histopathologic leaions in rats of 1 or 4 mg/m³ (0.2 or 0.8 ppm) groups was not significantly different than controls (exception of Goblet cell hyperplasia in the nasal and paranasal regions and main bronchi of rats in the 4 mg/m³ group)

 7 and 10 mg/m³ groups exhibited significant airway injury and decrement in pulmonary function consistent with the clinical signs of respiratory tract irritation

most of the signs regressed during the first post exposure week

* sporadic recurrence of irregular breathing patterns and wheezing was observed

necropsy findings in rats of these groups included macroscopic lung lesions and pleural

PHENYL ISOCYANATE AEGL-1

| | AEGL-1 values for phenyl isocyanate (ppm) | | | | | | | | |
|----------------|---|--------|--------|--------|--------|--|--|--|--|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h | | | | |
| AEGL-1 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | | | | |

Key study: Pauluhn, J., Rüngeler, W., Mohr, U. 1995. Phenyl isocyanate-induced asthma in rats following a 2-week exposure period. Fundam. Appl. Toxicol. 24: 217-228.

Critical effect/POD: threshold for respiratory tract irritation; 1.1 mg/m3 (0.2 ppm); 6-hr repeated exposure

Uncertainty factors: Total uncertainty factor adjustment is 30

<u>Interspecies</u>: 10; absence of human data and animal data in only one species justify retention of the default interspecies uncertainty factor of 10.

Intraspecies: 3; phenyl isocyanate is a direct-contact irritant; toxicodynamics would not be expected to vary; the POD appears to be a protective estimate (multiple exposures to higher concentrations produced no clinical signs or histopathologic evidence of pulmonary damage); isocyanates react with nucleophiles at the point of contact which, in respiratory tract tissue, includes proteins with sulfhydryl, hydroxyl, amine, and carboxyl groups (OECD, 2005). Pauluhn et al. (1995) noted that experimental evidence suggests that tissue damage is consistent with a persistent inflammatory response involving direct contact with the tissue.

Modifying Factor: none

Time scaling: $C^n \times t = k$, where n = 1 or 3


PHENYL ISOCYANATE Animal Lethality Data

- o Imperial Chemical Industries Limited (1980a)
 - o 4 d 4 Q rats/group exposed for 1 hour to 0.358, 1.325, 1.45, 2.167, 4.368, 6.08, 7.942, or 9.187
 - o 1-hour LCa; 3.9 ppm (2.9-5.3 ppm; 95% c.i.)
 - o delayed lethality
- o Baver AG (1981a)
 - o 5 of 5 \to Wistar rats exposed to a saturated atmosphere of phenyl isocyanate (~1600 ppm at 20 °C) for 3, 10, or 30 minutes; observation period 14 days
 - o all rats died
 - o time-to-death was inversely related to exposure duration (see table)
- o Baver AG (1991a)
 - o $4 \stackrel{?}{\circ} 4 \stackrel{?}{\circ}$ Wistar rats were exposed for 4 hrs to 0, 2.1, 10.4, 20.8, 31.3, 64.6, 82.9, or 150.2 mg/m ³ (equivalent to 0, 0.4, 2.2, 4.4, 6.6, 7.7, 17.4, and 31.3 ppm)
 - o clinical signs and gross path. findings indicated respiratory tract as primary target
 - o most rats died within 9 days
 - * 4-hr LC₅₀: 22 mg/m³ (19-27 mg/m³: 95% c.i.) (4.6 ppm)
 - * NOAEL: 0.7 mg/m³ (0.15 ppm)

PHENYL ISOCYANATE Animal Nonlethal

- o Monsanto (1954)
 - o no deaths in rats exposed for 4 hrs to ~29 ppm
- o Imperial Chemical Industries Limited (1980b)
 - o 8 ♂ 8 ♀ Wistar-derived rats exposed to 0.05 ppm or 0.5 ppm, 6 hrs/day for 11 days
 - o 0.05 ppm concentration was close to a no-effect level
- o Bayer AG (1991b)
 - o 10 & 10 \times Wistar rats/group exposed to 0, 0.12, 0.57, or 3.14 mg/m³ (analytically determined by HPLC analysis; equivalent to 0, 0.03, 0.1, or 0.7 ppm), 6 hrs/day for 5 days; 3-wk observation
 - o no rats died; no significant clinical signs in 0.03 or 0.1 ppm groups
 - o serous nasal discharge but no cumulative effects in the 0.7 ppm group
 - o multiple 6-hr exposures to 0.1 ppm were without serious effect
 - o multiple exposures at 0.7 ppm resulted in no significant toxicological consequences

| AEGL values for phenyl isocyanate (ppm) | | | | | | | |
|---|--------|--------|--------|--------|--------|--|--|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h | | |
| AEGL-1 (Nondisabling) | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | | |
| AEGL-2 (Disabling) | 0.027 | 0.027 | 0.027 | 0.027 | 0.027 | | |
| AEGL-3 (Lethality) | 0.10 | 0.10 | 0.079 | 0.050 | 0.050 | | |



PHENYL ISOCYANATE AEGL-2

| | AEGL-2 values for phenyl isocyanate (ppm) | | | | | | |
|----------------|---|--------|-------|-------|-------|--|--|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h | | |
| AEGL-2 | 0.027 | 0.027 | 0.027 | 0.027 | 0.027 | | |

Key study: Pauluhn, J., Rüngeler, W., Mohr, U. 1995. Phenyl isocyanate-induced asthma in rats following a 2-week exposure period. Fundam. Appl. Toxicol. 24: 217-228.

Critical effect/POD: 0.8 ppm, 6-hr repeated exposure; NOAEL for AEGL-2 severity effects based upon clinical signs, clinical chemistry evaluations and gross/histopathology findings.

Uncertainty factors: Total uncertainty factor adjustment is 30

<u>Interspecies</u>: 10; absence of human data and animal data in only one species justify retention of the default interspecies uncertainty factor of 10.

Intraspecies: 3; phenyl isocyanate is a direct-contact irritant; toxicodynamics would not be expected to vary; the POD appears to be a protective estimate (multiple exposures to higher concentrations produced no clinical signs or histopathologic evidence of pulmonary damage); isocyanates react with nucleophiles at the point of contact which, in respiratory tract tissue, includes proteins with sulfhydryl, hydroxyl, amine, and carboxyl groups (OECD, 2005). Pauluhn et al. (1995) noted that experimental evidence suggests that tissue damage is consistent with a persistent inflammatory response involving direct contact with the tissue.

Modifying Factor: none

Time scaling: $C^n \times t = k$, where n = 1 or 3

PHENYL ISOCYANATE AEGL-3

| AEGL-3 values for phenyl isocyanate (ppm) | | | | | | |
|---|--------|--------|-------|-------|-------|--|
| Classification | 10-min | 30-min | 1-h | 4-ь | 8-h | |
| AEGL-3 | 0.10 | 0.10 | 0.079 | 0.050 | 0.050 | |

Key study: Bayer, AG. 1991a. Phenyl isocyanate; Untersuchungen zur akuten inahlationstoxizität an der Ratte. Bercht- Nr. 20354. Studien-Nr. T7037386, Bayer AG Institut für Toxikologie

Critical effect/POD: 3-fold reduction of rat 4-hr LC_{50} (4.6 ppm/3 = 1.5 ppm) considered an estimate of the lethality threshold.

Uncertainty factors: Total uncertainty factor adjustment is 30

<u>Interspecies</u>: 10; absence of human data and animal data in only one species justify retention of the default interspecies uncertainty factor of 10.

Intraspecies: 3; phenyl isocyanate is a direct-contact irritant for which the dynamic aspect of toxicity would not be expected to vary. It has been reported that isocyanates react with nucleophiles at the point of contact which, in respiratory tract tissue, includes proteins with sulfhydryl, hydroxyl, amine, and carboxyl groups (OECD, 2005). Pauluhn et al. (1995) noted that experimental evidence suggests that tissue damage is consistent with a persistent inflammatory response involving direct contact with the tissue.

Modifying Factor: none

Time scaling: $C^n \times t = k$, where n = 1 or 3; the 10-minute value is held constant with the 30-min. value. The 8-hour AEGL-3 value was set equivalent to the 4-hour value to maintain consistency with the AEGL-2 values.

ACUTE EXPOSURE GUIDELINE LEVELS FOR METHYL ISOTHIOCYANATE (CH₃N=C=S)

National Advisory Committee for AEGLs Meeting-45 March 3-5, 2008

ORNL Staff Scientist: Sylvia S. Talmage

Chemical Manager: Susan Ripple

Chemical Reviewers: David Freshwater Ralph Gingell

METHYL ISOTHIOCYANATE

Studies reported from secondary sources

Solid, rapidly vaporizes Pungent, horse-radish-like odor Use – pesticide, injected into soil

Toxicity: isothiocyanates (R-N=C=S) less toxic than the isocyanates (R-N=C=O)

Clinical Study:

Odor and eye irritation threshold (Russell and Rush 1996)

Animal Studies:

Acute toxicity, rat – Clark and Jackson 1977; Clark et al. 1981
Repeat-exposure studies – Klimish 1987; Rosskamp et al. 1978
Metabolism study, rat – Lam et al. 1993
Developmental/Reproductive studies, rat and rabbit (oral): not a teratogen
Carcinogenicity studies, rat and mouse (oral): not carcinogenic

METHYL ISOTHIOCYANATE

Clinical Study

| Eye Irritation in Human Subjects | | | | | |
|----------------------------------|------------|------------|--|--|--|
| Exposure time | NOEL (ppm) | LOEL (ppm) | Effect | | |
| 1 minute | 3.3 | _ | _ | | |
| 4 minutes | 0.60 | 1.9 | Subjective eye irritation | | |
| 14 minutes | 0.60 | 1.9 | Subjective eye irritation | | |
| 1 hour | 0.23 | 0.80 | Subjective eye irritation | | |
| 1.5 hours | 0.22 | _ | _ | | |
| 2 hours | 0.23 | 0.80 | Subjective eye irritation and increased blink rate | | |
| 3 hours | 0.23 | 0.80 | Subjective eye irritation and increased blink rate | | |
| 3.5 hours | 0.22 | _ | | | |
| 4 hours | 0.23 | 0.80 | Subjective eye irritation | | |
| 6 hours | 0.22 | _ | _ | | |
| 8 hours | 0.22 | _ | _ | | |

The 0.22 and 0.23 ppm concentrations were used on different day

- = not tested

Source: Russell and Rush 1996; reported in Rubin et al. 2003.

LOELs were determined by statistical significance; variability was great among control and tested subjects. Irritation at the LOEL of 0.80 ppm was judged 25-26% on a scale of 1-100.

3

METHYL ISOTHIOCYANATE

Acute Toxicity Data - Rat

| Summary of Acute Lethal Inhalation Data in Laboratory Animals | | | | | | |
|---|---------------------|---------------|------------------|------------------------|--|--|
| Species | Concentration (ppm) | Exposure Time | Effect | Reference | | |
| Rat | 210 | l hour | No mortality | Clark and Jackson 1977 | | |
| | 635 | 1 hour | LC ₅₀ | | | |
| Rat | 80 | 4 hours | No mortality | Jackson et al. 1981 | | |
| | 180 | 4 hours | LC _{so} | | | |

METHYL ISOTHIOCYANATE

Repeat-Exposure Studies - Rat

| | TA | BLE 1. Summary | of Repeat-Exposure Studies | |
|---------|---------------------|------------------------|--|-----------------|
| Species | Concentration (ppm) | Exposure Time | | Reference |
| Rat | 1.7 | 6 hours/day, | No clinical signs | Klimisch 1987 |
| | 6.8 | 5 days/week 28 days | Eyelid closure, somnolence, ruffled fur | |
| | 34 | - | Eyelid closure, somnolence, ruffled fur, nasal discharge, | |
| | | | salivation, eye discharge, difficulty in breathing; nasal and lung lesions | , |
| Rat | 1 | 4 hours/day, | No clinical signs | Rosskamp et al. |
| | 10 | 5 days/week, | No clinical signs | 1978 |
| | 45 | 12-13 weeks | Apathetic appearance, salivation, nasal discharge, reduced body weight | |

METHYL ISOTHIOCYANATE

AEGL-1

Point of departure:

Clinical study: NOELs for eye irritation

14-minute exposure to 0.60 ppm

1-8 hour exposure to 0.22/0.23 ppm

Uncertainty factor (NOEL):

Intraspecies: 1, A NOEL for eye irritation is below the definition of an AEGL-1.

Alternate point of departure:

LOELs (slight) for eye irritation meet the definition of an AEGL-1.

Uncertainty factor (LOEL):

Intraspecies: 3, slight irritation should not vary greatly among individuals.

No time-scaling: there is adaptation to the slight irritation that defines the AEGL-1

METHYL ISOTHIOCYANATE

AEGL-2

No acute studies that meet the definition of an AEGL-2. In lethality studies, the dose-response curve is steep.

The AEGL-2 values can be derived by dividing the AEGL-3 values by 3 (NRC 2001).

METHYL ISOTHIOCYANATE

AEGL-3

Point of departure:

Highest non-lethal value - 4-hour exposure of rats to 80 ppm (Jackson et al. 1981)

Uncertainty factors:

Interspecies: 1, direct-acting irritant

Intraspecies; 3, direct-acting irritant

Application of greater uncertainty factors, 3 and 3 for a total of 10, would bring the 4-hour value to 8 ppm, a concentration inconsistent with the repeat-exposure studies. No rats died during exposures to 35 ppm, 6 hours/day, 5 days/week, for 28 days (Klimisch 1978) or to 45 ppm, 4 hour/day, 5 days/week for 12-13 weeks (Rosskamp et al. 1978.)

Time-scaling ($C^n \times t = k$):

Default values of n = 3 and n = 1 for shorter and longer exposure durations, respectively. The 10-minute value was set equal to the 30-minute value.


METHYL ISOTHIOCYANATE

| Proposed Methyl Isothiocyanate AEGL Values | | | | | | |
|--|-------------------|-----------|----------|----------|----------|--|
| | Exposure Duration | | | | | |
| Classification | 10-minute | 30-minute | 1-hour | 4-hour | 8-hour | |
| AEGL-1 | | | <u> </u> | | | |
| (NOEL) | 0.60 ppm | 0.22 ppm | 0.22 ppm | 0.22 ppm | 0.22 ppm | |
| (LOEL) | 0.63 ppm | 0.27 ppm | 0.27 ppm | 0.27 ppm | 0.27 ppm | |
| AEGL-2 | 26 ppm | 18 ppm | 14 ppm | 9.0 ppm | 4.3 ppm | |
| AEGL-3 | 77 ppm | 53 ppm | 42 ppm | 27 ppm | 13 ppm | |

AEGL-1: NOEL, LOEL for eye irritation - clinical study of 1 minute to 8 hours

AEGL-2: AEGL-3 divided by 3

AEGL-3: Highest non-lethal concentration - 4-hour exposure of rats to 80 ppm



METHYL ISOTHIOCYANATE

| | Proposed Methyl Isothiocyanate AEGL Values | | | | | | |
|----------------|--|-------------------|----------|----------|----------|--|--|
| | | Exposure Duration | | | | | |
| Classification | 10-minute | 30-minute | 1-hour | 4-hour | 8-hour | | |
| AEGL-1 | | | | | | | |
| (NOEL) | 0.60 ppm | 0.22 ppm | 0.22 ppm | 0.22 ppm | 0.22 ppm | | |
| (LOEL) | 0.63 ppm | 0.27 ppm | 0.27 ppm | 0.27 ppm | 0.27 ppm | | |
| AEGL-2 | 26 ppm | 18 ppm | 14 ppm | 9.0 ppm | 4.3 ppm | | |
| AEGL-3 | | | | | | | |
| (4 hours) | 77 ppm | 53 ppm | 42 ppm | 27 ppm | 13 ppm | | |
| (1 hour) | 127 ppm | 88 ppm | 70 ppm | 18 ppm | 8.8 ppm | | |

AEGL-1: NOEL, LOEL for eye irritation - clinical study of 1 minute to 8 hours

AEGL-2: AEGL-3 divided by 3

AEGL-3: Highest non-lethal concentration – 4-hour exposure of rats to 80 ppm;

" 1 hour exposure of rats to 210 ppm.

11

ATTACHMENT 11

ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) FOR ETHYL PHOSPHORODICHLORIDATE

NAC/AEGL-45 March 3-5, 2008 Alexandria, VA

ORNL Staff Scientist: Cheryl Bast

Chemical Manager: Gail Chapman

Chemical Reviewers: Dieter Heinz and Martha Steele

| AEGL-1 VALUES: ETHYL PHOSPHORODICHLORIDATE | | | | | | |
|--|-----------|--------|--------|----|--|--|
| 10 minute | 30 minute | 1 hour | 8 hour | | | |
| NR | NR | NR | NR | NR | | |

NR: Not Recommended due to insufficient data.

Limited Database:

No human Data

Acute Inhalation data limited to rats:

1-hr range-finding study (Rhone-Poulenc, Inc., 1990)

4-hr acute toxicity study (Bayer, 1983)

Mechanism:

Primary Irritation

Rat studies suggest that vapors are irritating to the eyes and nose, and that pulmonary edema increases as concentration increases (Rhone Poulenc, Inc., 1990; Bayer, 1983).

The liquid was corrosive to the skin and eyes of rabbits (Rhone Poulenc, Inc., 1990).

May react with water to produce hydrogen chloride fumes

| AEGL-2 Values for ETHYL PHOSPHORODICHLORIDATE | | | | | | | |
|---|-------------------|----------|----------|----------|--|--|--|
| 10-min | 30-min 1-h 4-h 8- | | | | | | |
| 0.76 ppm | 0.76 ppm | 0.60 ppm | 0.38 ppm | 0.19 ppm | | | |
| | | | | | | | |

Endpoint: Ten-fold reduction of AEGL-3 values.

SOP (NRC, 2001):

In the absence of appropriate chemical-specific data, a fractional reduction of the AEGL-3 values may be used to derive AEGL-2 values.


In cases of a steep-concentration-response curve, AEGL-3 values may be divided by 3 to estimate AEGL-2 values.

DERIVATION RATIONALE:

4-Hour rat lethality data suggest that the concentration-response curve is not steep (Bayer, 1983):

| Concentration | Mortality |
|---------------|-----------|
| 37 ppm | 0% |
| 61 ppm | 20% |
| 75 ppm | 20% |
| 90 ppm | 60% |
| 143 ppm | 85% |
| 355 ppm | 100% |

Therefore, the factor of 3 is not considered sufficient, and AEGL-2 values are estimated by dividing AEGL-3 values by 10.



| Concentration (ppm) | Body w (grams; mea | ~ | Terminal lung weight (grams; mean ± SD) | | Mortality incidence | | |
|-------------------------------|---|--|--|------------------------|---------------------|--------|------|
| | Male | Female | Male | Female | Male | Female | Tota |
| 6.16 | Day 1: 248±15 (5) Day 8: 287±17 (5) Day 15: 334±30 (5) | Day 1: 198±7 (5) Day 8: 222±6 (5) Day 15: 236±5 (5) | 1.360±0.111 | 1.099±0.065 | 0/5 | 0/5 | 0/10 |
| 66 | Day 1: 331±18 (5) Day 8: - (0) Day 15: - (0) | Day 1: 238±11 (5) Day 8: 203±33 (3) Day 15: 252±51 (2) | • | 1.933±0.215 | 5/5 | 3/5 | 8/10 |
| 134 | Day 1: 286±16 (5) Day 8: 206±35 (4) Day 15: 246±105 (2) | Day 1: 200±14 (5) Day 8: 181±0 (1) Day 15: 237±0 (1) | 1.929± 0.402 | 2.40 8±0 .0 | 3/5 | 4/5 | 7/10 |
| LC ₅₀ (ppm) | | | | | 64.6 | 48.1 | 43.4 |
| BMCL ₀₅ (ppm)** | | - | | | 0.10 | 0.71 | 1.28 |
| BMC ₀₁ (ppm)** | | | | | 2.39 | 7.50 | 3.85 |

Rhone-Poulenc, Inc., 1990; ** Values calculated for this TSD.

| 7.6 ppm | 10 minute | AEGL-3 |
|---------|---------------------|---|
| 7.6 ppm | 10 minute 30 minute | VALUES: E' |
| 6.0 ppm | 1 hour | AEGL-3 VALUES: ETHYL PHOSPHORODICHLORIDATE |
| 3.8 ppm | 4 hour | HORODICHL |
| 1.9 ppm | 8 hour | ORIDATE |

Time: Endpoint: Reference: Species: Concentration: The 4-hour study was chosen over the 1-hour study because it includes more animals per exposure group and yields a better concentration-response relationship. Furthermore, the goodness of fit for the benchmark calculations is better for the 4-hour data. Rat
38.0 ppm
4 hours
BMCL₀₅ (male and female combined)
Bayer, 1983

Time Scaling: $c^n \ x t = k$, where the exponent, n, is the conservative default of 1 (8-hr) or 3 (30-min. and 1-hr. 30-Min value is adopted as 10-min value)

Uncertainty Factors: Interspecies = 3: Irritant Intraspecies = 3: Irritant

Portal of entry/primary irritant effects are not expected to vary greatly within or between species.

| AEGL Values for Ethyl phosphorodichloridate | | | | | | |
|---|----------|----------|----------|----------|----------|--|
| Classification | 10-min | 30-min | 1-h | 4-h | 8-h | |
| AEGL-1 (Nondisabling) | NR | NR | NR | NR | NR | |
| AEGL-2 (Disabling) | 0.76 ppm | 0.76 ррш | 0.60 ppm | 0.38 ppm | 0.19 ррш | |
| AEGL-3 (Lethality) | 7.6 ppm | 7.6 ppm | 6.0 ppm | 3.8 ppm | 1.9 ppm | |

NR: Not Recommended due to insufficient data. Absence of an AEGL-1 value does not imply that concentrations below the AEGL-2 are without effect.

There are no other standards or guidelines for ethyl phosphorodichloridate!

| Concentration (nam) | | Mortality incide | nce |
|-----------------------------|-------|------------------|-------|
| Concentration (ppm) | Male | Female | Total |
| 37 | 0/10 | 0/10 | 0/20 |
| 61 | 2/10 | ** | 2/10 |
| 75 | 1/10 | 3/10 | 4/20 |
| 90 | 7/10 | 5/10 | 12/20 |
| 143 | 10/10 | 7/10 | 17/20 |
| 355 | 10/10 | 10/10 | 20/20 |
| LC ₅₀ (ppm) | 85 | 99.8 | 91.6 |
| BMCL ₀₅ (ppm)*** | 43.7 | 25.8 | 38.0 |
| BMC ₀₁ (ppm)*** | 48.1 | 32.1 | 38.2 |

^{*}Bayer, 1983; **Data not reported. No explanation provided; *** Values calculated for this TSD.

ACUTE EXPOSURE GUIDELINE LEVELS **FOR** 1.2-BUTYLENE OXIDE (C₄H₈O)

National Advisory Committee for AEGLs Meeting-45 March 3-5, 2008

ORNL Staff Scientist:

Svlvia S. Talmage

Chemical Manager:

Jim Holler

Chemical Reviewers:

Alan Woolf Lynn Beasley

1,2-BUTYLENE OXIDE

Highly flammable, reactive liquid at ambient temperature Pungent odor

Use – stabilizer in hydrocarbon solvents

Clinical Studies:

No data

Animal Studies:

Acute toxicity, rats and mice - NTP 1988

Repeat-exposure toxicity studies, rat and mouse - (Miller et al. 1981; NTP 1988)

Metabolism study, rat - Reitz et al. 1983

Conjugated with glutathione

Developmental/Reproductive studies (Sikov et al. 1981)

Effects on the fetus only at maternally toxic concentrations

Genotoxicity studies (NTP 1988)

Positive in several tests

Chronic Toxicity/Carcinogenicity study

Male rats - nasal neoplasms (NTP 1988)

1.2-BUTYLENE OXIDE

Effects:

Acute: Direct acting irritant

Target - eve, respiratory tract

Chronic: Carcinogenic in rats, not in mice

Target - nasal mucosa

ATTACHMENT 12

1.2-BUTYLENE OXIDE

Acute Toxicity Data - Rat

NTP (1988) - 4 hour study

Effect Concentration

398 ppm

No signs reported

721 ppm

No signs reported Signs of eye irritation

1420 ppm 2050 ppm

Ocular discharge, dyspnea

6550 ppm

Dyspnea, death of 10 of 10 rats

Reitz et al. 1983 - 6 hour study

Concentration

Effect

50 ppm

No effect reported

1000 ppm

Moderate respiratory rate decrease

Support Studies - Repeat-exposure, Rat, mouse

Miller et al. 1981; NTP 1988

Concentration

Effect

400 ppm, 6 hours/day, 2 weeks

No lesions

1.2-BUTYLENE OXIDE

AEGL-1

Point of departure:

NOAEL for eve irritation – 4-hour exposure of rats to 721 ppm (NTP 1988)

Uncertainty factors:

Interspecies: 3: slight irritation from a direct-acting irritant should not vary greatly between species

Intraspecies: 3: slight irritation from a direct-acting irritant should not vary greatly among individuals

Application of greater uncertainty factors, 3 and 10 for a total of 30, would bring the 4hour value to 24 ppm, 16-fold less than the no effect concentration of 400 ppm in repeat-exposure studies (Miller et al. 1981; NTP 1988)

Time-scaling:

No time scaling – there is adaptation to the slight irritation that defines the AEGL-1. The 8-hour value was adjusted by a MF of 2.

5

1.2-BUTYLENE OXIDE

AEGL-2

Point of departure:

Moderate eye irritation – 4-hour exposure of rats to 1420 ppm (NTP 1988) Support: Moderate decrease in respiratory rate – 6-hour exposure to 1000 ppm (Reitz et al. 1983)

Uncertainty factors:

Interspecies: 3, direct-acting irritant Intraspecies: 3, direct-acting irritant

Application of greater uncertainty factors, 3 and 10 for a total of 30, would bring the 4hour value to 47 ppm, 10-fold less than the no effect concentration of 400 ppm in repeat-exposure studies (Miller et al. 1981; NTP 1988)

Time-scaling ($C^n \times t = k$):

Default values of n = 3 and n = 1 for shorter and longer exposure durations. respectively. The 10-minute value was set equal to the 30-minute value.

1.2-BUTYLENE OXIDE

AEGL-3

Point of departure:

Highest non-lethal value – 4-hour exposure of rats to 2050 ppm (NTP 1988)

Uncertainty factors:

Interspecies: 3, direct-acting irritant Intraspecies: 3, direct-acting irritant

Application of greater uncertainty factors, 3 and 10 for a total of 30, would bring the 4hour values to 68 ppm, approximately 6-fold less than the no effect concentration of 400 ppm in repeat-exposure studies (Miller et al. 1981; NTP 1988)

Time-scaling ($C^n \times t = k$):


Default values of n = 3 and n = 1 for shorter and longer exposure durations. respectively. The 10-minute value was set equal to the 30-minute value.

1.2-BUTYLENE OXIDE


| Proposed 1,2-Butylene Oxide AEGL Values | | | | | |
|---|-------------------|-----------|---------|---------|---------|
| | Exposure Duration | | | | |
| Classification | 10-minute | 30-minute | 1-hour | 4-hour | 8-hour |
| AEGL-1 | 72 ppm | 72 ppm | 72 ppm | 72 ppm | 36 ppm |
| AEGL-2 | 280 ppm | 280 ppm | 230 ppm | 140 ppm | 71 ppm |
| AEGL-3 | 410 ppm | 410 ppm | 325 ppm | 200 ppm | 100 ppm |

AEGL-1: NOAEL for eye irritation - 4-hour exposure of rats to 721 ppm AEGL-2: Moderate eye irritation - 4-hour exposure of rats to 1421 ppm

AEGL-3: Highest non-lethal concentration - 4-hour exposure of rats to 2050 ppm



Q





Objective

· Introduce Benchmark Dose Modeling and its application in dose-response analysis for the data obtained from animal studies.



Outline

- · Introduction to benchmark dose method
 - -Traditional method (NOAEL)
 - -Concept of BMD method
 - -Pros and cons for BMD method
- · EPA's BMD software (BMDS) and its available models
- · BMD modeling procedure
- · Evaluation of BMD modeling results



Glossary

- BMD: An estimate of the dose or concentration that produces a predetermined change in response rate
 BMDL: 95% lower-bound confidence limit on the BMD
 BMR: A predetermined response level based on which a BMD or BMDL is calculated
- POD: a point of departure used in estimate risk values when divided by an uncertainty factor
- UF: Factors used in risk assessment to account for uncertainty in the data or extrapolations to human no-effect levels
- Confidence interval: an interval estimate of a population parameter at a certain confidence level
- AIC: Akaike's Information Criterion used to assist in model evaluation based on overall data fitting and number of parameters used in the model


Reference Dose/Reference Concentration


RefD or RfC =


NOAEL or LOAEL

UF

NOAEL or LOAEL: No or Low Observed Adverse Effect Level UF: Uncertainty Factor











Limitations of Using a NOAEL or LOAEL

- · Limited to the doses tested
- · Response levels not comparable
- · Does not represent 0% response
- · Not always available
- Does not consider dose-response slope ("Wastes" data)
- · Highly dependent on sample size







Benchmark Dose Definitions

BMD: An estimate of the dose or concentration that produces a predetermined change in response rate of an adverse effect (called the benchmark response or BMR) compared to background.

 For example, an estimate of the dose that causes a 10% increase in the number of animals developing fatty liver compared with untreated animals.



Benchmark Dose Definitions

BMDL: 95% Lower-Bound Confidence Limit on the BMD.



Benchmark Dose

 Goal is to estimate a point of departure (POD) that is relatively independent of study design.



Deriving an RfD using a BMD

Equation for an RfD or RfC becomes:

RfD or RfC =

BMDL or BMCL

UF

No UF for LOAEL to NOAEL extrapolation

SEPA
United States
Environmental
Agency

Advantages of BMD Approach

- Not limited to doses tested experimentally
- · Less dependent on dose spacing
- Takes into account the shape of the dose-response curve
- Flexibility in determining biologically significant rates
- · Comparable results across chemicals and endpoints
- Incentive to conduct better (larger) studies (less uncertainty)



Challenges in the Use of BMD

- Ability to estimate a BMD may be limited by the format of the data presented
- · Generally more complicated and time consuming



Are the Data Worth Modeling?

- · Evaluate database as for NOAEL approach
 - -good quality studies
 - -appropriate duration and route of exposure
 - -measured endpoints of concern



Are the Data Worth Modeling?

- · Significant dose-related trend
- Two doses with responses in excess of the control
- Responses that define the low end of the doseresponse region are preferred



Are the Data Worth Modeling?

- Model all biologically, statistically significant responses, if feasible
- Model all the endpoints with LOAEL < 10-fold above the lowest LOAEL of the database
- Consider dropping high dose group(s) that negatively impact low dose fit



Benchmark Dose Software

- Benchmark Dose Software is also called BMDS software
- It is developed by US EPA and it is free available from website: www.epa.gov/ncea/bmds.



Types of Models

- · Dichotomous Model: for dichotomous or quantal data
- · Continuous Model: for continuous data
- · Nested Model: for nested dichotomous data



Model Selection - Dichotomous Data

- Dichotomous models are used to evaluate quantal data, where an effect for an individual may be classified by one of two possible outcomes.
- For example: dead or alive, tissue pathology (present/absent), and cancer incidence (yes/no)



BMDS Models for Dichotomous Data

- Gamma
- Logistic
- -Dose
- ~Log dose
- Probit
- -Dose
- --Log dose
- Multi-stageWeibull
- -Quantal-Linear (power = 1)




Model Selection - Continuous Data

- · Effects measured on a continuum
- For example: body weight, organ weight, enzyme levels



BMDS Models for Continuous Data

- · Polynomial (all-purpose model)
- -Linear (simplest model)
- -Non linear
- · Power (L-shaped dose-responses)
- -Linear
- -Non linear
- · Hill (dose-responses that plateau)





Nested Dichotomous Data

- · Malformation in neonates
- -Sternebral defect
- -Vertebral arch defect
- · Ossification changes in neonates




BMDS Models for Nested Dichotomous

- · Logistic Nested Model (NLogistic)
- · NCTR
- · Rai & Van Ryzin Model



Model Selection – Other Considerations?


- Most BMD models are not biologically based, but all model fits must be biologically tenable
- To be biologically tenable, model parameters may need to be restricted
- Consider using model with asymptote term for saturable responses





Select A Benchmark Response

- BMR should be near the low end of the range of increased risks that can be detected by a bioassay.
- Low BMRs can impart high model dependence, i.e., different models will provide different BMDL estimates.





BMR Selection: Choose BMR(s) (Dichotomous Data)

- Extra risk of 10% is the default BMR, since the 10% response is at or near the limit of sensitivity in most cancer bioassays and in some non-cancer bioassays.
- If a study has greater than usual sensitivity, a lower BMR can be used.
- BMD10 and BMDL10 should always be presented for comparison purpose.




BMR Selection: Choose BMR(s) (Continuous Data)


- If there is an accepted level of change in the endpoint that is considered to be biologically significant, then that amount of change is the BMR.
- In the absence of any other idea of what level of response to consider adverse, a change in the mean equal to one control standard deviation (1.0 SD) from the control mean can be used.





Restricting Parameters

- BMD Guidance suggests restricting models initially.
- · Unrestricted, some models take on unrealistic forms.
- Number of parameters in a model cannot exceed the number of dose groups.











Does the Model Fit the Data?

- Global measurement: goodness-of-fit p value (p > 0.1)
- Local measurement: Scaled residuals (absolute value < 2.0)
- · Visual inspection of model fitting

Note: Consider how well the model predicts both responses and response variance (in the case of continuous data).



Have All Options Been Considered?

- Goal of BMD modeling fit a model to dose-response data that describes the data, especially at the lower end of the dose-response range.
- This may require the application of several models and model options, or just a few.



Summary of BMD Results

| Model | P value | AC | Residual at 0 | Residual at 5% | BMD | BMDL |
|----------------|---------|-------|------------------|-------------------|------|---------|
| Gamma | 0.9032 | 295.6 | 0 | 0.230 | 64.3 | 54.5 |
| Logistic | | | | | | |
| Log-Logistic | | | | | | |
| Multistage | | | | | | |
| Probit | | | | | | |
| Log-Probit | | | | | | |
| Quantal-Linear | | | | | | |
| Weibuli | - | | | | | |



BMDL Estimates Within 3-fold Range?

- Often, more than one model will result in an acceptable fit to the data.
- Consider using the lowest BMDL if BMDL estimates from acceptable models are widely divergent (e.g., outside of a 3-fold range).
- Consider relative model fit of BMDL if model results in similar BMDL estimates (e.g., within a 3-fold range).



≎EPA

Environmental Pro Agency

is There One Model That Fits the Data Best?

- Global measurement: goodness-of-fit p value (p > 0.1)
- · Local measurement: Scaled residuals near the BMR
- Visual comparison of model fits (e.g., to detect systemic or high dose bias)
- Comparison of Akaike's Information Criterion (AIC) (smaller is better)



Akaike's Information Criterion (AIC)

 $AIC = -2 \times LL + 2 \times P$

- LL = log-likelihood at the maximum likelihood estimates for parameters
- p = number of model parameters estimated
- Within a family of models, fit will improve as parameters are added.
- For a similar degree of fit, AIC rewards the less complex model (with less parameters).



Summary of BMD Results

| Model | Pvalue | AIC | Residual at 0 | Residual at 5% | BMD | BMDL |
|----------------|--------|-------|------------------|-------------------|------|------|
| Gamma | 0.9032 | 295.6 | 0 | 0.230 | 64.3 | 54.5 |
| Logistic | 0.3317 | 298.5 | -0.996 | -0.246 | 70.5 | 61.8 |
| Log-Logistic | 0.8851 | 295.6 | 0 | 0.287 | 65.1 | 55.3 |
| Multistage | 0.2520 | 297.9 | 0 | -1.545 | 51.3 | 45.7 |
| Probit | 0.6543 | 296.6 | -0.628 | -0.077 | 67.8 | 58.9 |
| Log-Probit | 0.6513 | 296.2 | 0 | 0.443 | 63.7 | 54.9 |
| Quantel-Linear | 0 | 324.4 | 0 | -3.69 | 24.1 | 20.5 |
| Weibuli | 0.9912 | 295.4 | 0 | -0.083 | 64.3 | 53.7 |



Deriving an RfD/RFC from a BMDL

$$RfD or RfC = \frac{BMDL or BMCL}{UF}$$



Conclusion

- · BMD method uses more dose-response information.
- · It provides a better way for comparing different endpoints.
- This method gives incentive to conduct better studies (with less uncertainty).
- BMD modeling requires more information on the data and it is more time consuming.



References

- Collins, J. F., Alexeeff, G. V., Lewis, D. C., Dodge, D. E., Marty, M. A., P. Lam, R. H., Lipsett, M. J., Fowles, J. R., & Das, R. (2004). Development exposure levels (RELs) to protect the public from predictable excursions of 10stool, 24(2), 155-166.
- Crump, K. (2002). Critical Issues in Benchmark Celculations from Continuous Data. <u>Critical Reviews</u> in <u>Toxicology</u>, *32*(3), 133-153.
- п. тэмэслиуг, 3д(э), 135-153. Crump, K. S. (1984). A new method for determining allowable daily intakes. Funds 4(5), 854-871.
- Filipseon, A. F., Sand, S., Nilsson, J., & Victorin, K. (2003). The benchmark dose method-review of svallable models, and recommendations for application in health risk assessment. <u>Crit Rev Toxicol</u>, 32(5), 505-56.
- 33(5), 505-542.

 U.S. Environmental Protection Agency. (1995). The Use of the Benchmark Dose Approach in Hear Risk Assessment (EPAR30R-94/007): Office of Research and Development. (http://cryub.epa.gov/incsa/rafirecordisplay.cfm?deid=42501)
 U.S. Environmental Protection Agency. (2000). Benchmark Dose Technical Guidence Document. External Review Draft (EPAR30R-00001). Washington, DC: Risk Assessment Forum. (http://www.epa.gov/incsa/pdis/bmds/BMD-External_10_13_2000.pdf)
 U.S. Environmental Protection Agency. (2007). BenchMark Dose Software (Version 1.4.1c): Nation Center for Environmental Assessment. (http://www.epa.gov/incsa/bmds/)